NASDAQ:VALN Valneva (VALN) Stock Price, News & Analysis $7.25 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.21▼$7.2650-Day Range$6.92▼$9.0852-Week Range$6.58▼$15.28Volume1,907 shsAverage Volume9,932 shsMarket Capitalization$504.88 millionP/E RatioN/ADividend YieldN/APrice Target$21.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Valneva alerts: Email Address Valneva MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside198.9% Upside$21.67 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.50) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.88 out of 5 starsMedical Sector666th out of 936 stocksBiological Products, Except Diagnostic Industry108th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingValneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageValneva has only been the subject of 1 research reports in the past 90 days.Read more about Valneva's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.09% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Valneva has recently decreased by 22.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldValneva does not currently pay a dividend.Dividend GrowthValneva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VALN. Previous Next 2.0 News and Social Media Coverage News SentimentValneva has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Valneva this week, compared to 4 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Valneva insiders have not sold or bought any company stock.Percentage Held by Insiders14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.39% of the stock of Valneva is held by institutions.Read more about Valneva's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Valneva are expected to decrease in the coming year, from ($0.50) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Valneva is -17.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Valneva is -17.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioValneva has a P/B Ratio of 3.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Valneva's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Valneva Stock (NASDAQ:VALN)Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.Read More VALN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VALN Stock News HeadlinesJuly 26 at 1:55 AM | americanbankingnews.comBrokers Offer Predictions for Valneva SE's Q3 2024 Earnings (NASDAQ:VALN)July 24 at 4:18 AM | americanbankingnews.comValneva's (VALN) "Buy" Rating Reiterated at HC WainwrightJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 23 at 7:06 AM | msn.comExperimental Lyme disease vaccine passes milestoneJuly 22, 2024 | markets.businessinsider.comStrong Buy Rating for Valneva as Ixchiq Vaccine Shows Significant Market PotentialJuly 22, 2024 | finance.yahoo.comCEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya VaccineJuly 22, 2024 | globenewswire.comCEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya VaccineJuly 21, 2024 | americanbankingnews.comValneva (NASDAQ:VALN) Shares Gap Down to $7.69July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 20, 2024 | markets.businessinsider.comKepler Capital Keeps Their Buy Rating on Valneva (0OB3)July 20, 2024 | finance.yahoo.comGlobal tech outage creates challenges for Canadian health infrastructureJuly 20, 2024 | msn.comTwo deaths linked to listeria food poisoning from meat sliced at deli countersJuly 19, 2024 | finance.yahoo.comPFE Jul 2024 41.000 put (PFE240719P00041000)July 17, 2024 | globenewswire.comPhase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series CompletionJuly 1, 2024 | globenewswire.comValneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ®June 26, 2024 | globenewswire.comValneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its BoardJune 24, 2024 | globenewswire.comValneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ®June 5, 2024 | globenewswire.comValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate UpdateSee More Headlines Receive VALN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)9/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VALN CUSIPN/A CIK1836564 Webvalneva.com Phone33-2-28-07-37-10FaxN/AEmployees676Year FoundedN/APrice Target and Rating Average Stock Price Target$21.67 High Stock Price Target$26.00 Low Stock Price Target$17.00 Potential Upside/Downside+200.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,780,000.00 Net Margins-15.88% Pretax Margin-64.16% Return on Equity-14.56% Return on Assets-4.78% Debt Debt-to-Equity Ratio0.84 Current Ratio2.64 Quick Ratio2.22 Sales & Book Value Annual Sales$165.52 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book3.61Miscellaneous Outstanding Shares69,640,000Free Float59,255,000Market Cap$502.10 million OptionableNot Optionable Beta2.20 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Thomas Lingelbach (Age 61)President, CEO & Director Comp: $997.45kMr. Peter Buhler (Age 53)Chief Financial Officer Comp: $606.17kMr. Frederic Jacotot (Age 60)VP of Legal & IP, General Counsel, and Corporate Secretary Comp: $331.05kMr. Franck Grimaud MBA (Age 57)Chief Business Officer Comp: $435.33kDr. Juan-Carlos Jaramillo M.D. (Age 52)Chief Medical Officer Comp: $585.47kMs. Dipal Patel (Age 49)Chief Commercial Officer Comp: $560.52kMr. Vincent Dequenne (Age 57)Chief Operating Officer Mr. Joshua Drumm Ph.D.Vice President of Investor RelationsMs. Laetitia Bachelot-FontaineVP of Global Communications & European Investor RelationsMs. Petra Pesendorfer (Age 38)Chief People Officer More ExecutivesKey CompetitorsImmunocoreNASDAQ:IMCRNeumora TherapeuticsNASDAQ:NMRABioCryst PharmaceuticalsNASDAQ:BCRXSana BiotechnologyNASDAQ:SANAVir BiotechnologyNASDAQ:VIRView All CompetitorsInstitutional OwnershipAlphaCentric Advisors LLCBought 26,248 shares on 7/26/2024Ownership: 0.127%General American Investors Co. Inc.Bought 9,361 shares on 5/3/2024Ownership: 0.509%View All Institutional Transactions VALN Stock Analysis - Frequently Asked Questions How have VALN shares performed this year? Valneva's stock was trading at $10.37 at the start of the year. Since then, VALN stock has decreased by 30.1% and is now trading at $7.25. View the best growth stocks for 2024 here. How were Valneva's earnings last quarter? Valneva SE (NASDAQ:VALN) posted its quarterly earnings results on Tuesday, May, 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.12. The company had revenue of $35.56 million for the quarter, compared to the consensus estimate of $95.80 million. Valneva had a negative trailing twelve-month return on equity of 14.56% and a negative net margin of 15.88%. When did Valneva IPO? Valneva (VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO. Who are Valneva's major shareholders? Top institutional investors of Valneva include AlphaCentric Advisors LLC (0.13%). How do I buy shares of Valneva? Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VALN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.